Mecobalamin

Eisai Saudi Arabia, a wholly-owned subsidiary of Eisai Europe, began operations in April 2024 to build an in-house sales system in Saudi Arabia. The company started selling Methycobal and Fycompa in October 2024 and plans to include Lenvima and Halaven from April 2025. An application for Alzheimer’s treatment lecanemab has been submitted for review. Eisai aims to deliver innovative drugs quickly and improve patient benefits.

Eisai Co., Ltd. announces the start of operations at Eisai Saudi Arabia, a wholly-owned subsidiary in Riyadh, focusing on pharmaceutical sales. Established in April 2024, it aims to build an in-house sales system, taking over commercial rights from local partners. The company plans to expand its product portfolio, including Methycobal, Fycompa, Lenvima, and Halaven, and has submitted an application for Alzheimer’s treatment lecanemab. Saudi Arabia’s pharmaceutical market, the largest in the Middle East, grew at an average rate of 7% from 2019 to 2023.

SmartyPants Vitamins launches Kids Triple Action Immunity gummies, containing 67% more nutrients than leading kids immunity gummies, with Vitamin C, D, and Zinc, plus ElderCraft® for antioxidant support. The product is a Clean Label Project® Purity Award Winner, free from major allergens, GMOs, gluten, synthetic colors, and certified vegetarian.